相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。
Article
Biochemistry & Molecular Biology
Todd Hollon et al.
Summary: DeepGlioma is a multimodal deep learning approach that utilizes stimulated Raman histology and large-scale public genomic data to accurately predict molecular alterations for diffuse glioma diagnosis.
Article
Biochemistry & Molecular Biology
Ingo K. Mellinghoff et al.
Summary: In a pilot perioperative randomized clinical trial, the dual IDH1/IDH2 inhibitor vorasidenib was found to have better brain permeability and target engagement than ivosidenib in patients with IDH1-mutant glioma. Both agents showed significant reduction in tumor 2-HG concentrations, with vorasidenib demonstrating more consistent suppression. Exploratory analyses revealed additional positive effects of 2-HG reduction. Vorasidenib was selected for further testing in phase 3 trials. This study was funded by Agios Pharmaceuticals, Inc. and Servier Pharmaceuticals LLC.
Article
Medicine, General & Internal
Ingo K. Mellinghoff et al.
Summary: In a phase 3 trial, vorasidenib showed significant improvement in progression-free survival and delay in the time to the next intervention for patients with grade 2 IDH-mutant glioma.
NEW ENGLAND JOURNAL OF MEDICINE
(2023)
Article
Multidisciplinary Sciences
Thomas Roetzer-Pejrimovsky et al.
Summary: Currently, there are approximately 150 different types of brain tumors defined by the WHO. However, the use of machine learning and deep learning methods for more precise diagnostics based on histopathological tumor appearance has been hindered by the lack of accessible digital histopathological datasets. To address this need, a significant portion of a large brain tumor bank at the Medical University of Vienna has been digitized, providing a unique dataset for potential use in machine learning and digital image analysis, teaching, and external validation.
Review
Oncology
C. Mircea et al.
Summary: This systematic review provides an overview of clinically relevant molecular markers in IDH-mutant astrocytomas grade 2 to 4. Multiple genetic and epigenetic markers are associated with patient outcome, involving the RB signaling pathway, the RTKPI3K-mTOR signaling pathway, genomic stability markers, and (epigenetic) gene regulation.
EUROPEAN JOURNAL OF CANCER
(2022)
Article
Oncology
Sybren L. N. Maas et al.
Summary: Utilizing DNA methylation and copy-number information for risk stratification in meningiomas improves prediction accuracy, with an integrated score showing higher precision, especially in risk separation of WHO grade 1 and grade 2 tumors.
JOURNAL OF CLINICAL ONCOLOGY
(2021)
Article
Oncology
C. Mircea S. Tesileanu et al.
Summary: This study examined the molecular and clinical factors related to outcomes in IDH1/2-mutant anaplastic astrocytoma patients. Both epigenetic classifiers and independent prognostic factors were identified for poor prognosis. These results will help improve the current WHO criteria for glioma classification.
Article
Oncology
Ingo K. Mellinghoff et al.
Summary: Vorasidenib demonstrated favorable safety profile and preliminary antitumor activity in patients with non-enhancing mIDH LGG, with a median progression-free survival of 36.8 months.
CLINICAL CANCER RESEARCH
(2021)
Review
Oncology
David N. Louis et al.
Summary: The fifth edition of the WHO Classification of Tumors of the Central Nervous System integrates molecular diagnostics into CNS tumor classification, introduces different approaches to tumor nomenclature and grading, and emphasizes the importance of integrated diagnoses and layered reports.
Article
Clinical Neurology
Mitsuaki Shirahata et al.
ACTA NEUROPATHOLOGICA
(2018)
Review
Clinical Neurology
Martin J. van den Bent
ACTA NEUROPATHOLOGICA
(2010)
